Version history

{
  "session_id": "sess_SDA-2026-04-02-gap-crispr-neurodegeneration-20260402",
  "round_number": 0,
  "agent_persona": "persona-theorist",
  "agent_backend": "claude-sonnet-4",
  "action": "propose",
  "content": "Based on the provided literature on CRISPR-based therapeutic approaches for neurodegeneration, here are 7 novel therapeutic hypotheses:\n\n## 1. Epigenetic Memory Reprogramming for Alzheimer's Disease\n**Description:** Utilize CRISPR-based epigenome editing to establish persistent transcriptional memory circuits that maintain neuroprotective gene expression patterns in vulnerable brain regions. By creating stable epigenetic marks at key neuroprotective loci, this approach could provide long-lasting therapeutic effects with minimal repeated interventions.\n\n**Target gene/protein:** BDNF, CREB1, and synaptic plasticity genes\n\n**Supporting evidence:** PMID:33838111 demonstrates genome-wide programmable transcriptional memory by CRISPR-based epigenome editing, showing the feasibility of creating persistent epigenetic modifications.\n\n**Confidence:** 0.7\n\n## 2. Cholesterol-CRISPR Convergence Therapy for Neurodegeneration\n**Description:** Engineer CRISPR systems to simultaneously target cholesterol metabolism genes while activating neuronal repair pathways. This dual approach leverages the critical role of cholesterol homeostasis in neurodegeneration and could address both metabolic dysfunction and direct neuroprotection.\n\n**Target gene/protein:** HMGCR, LDLR, and APOE regulatory regions\n\n**Supporting evidence:** PMID:41062796 highlights cholesterol metabolism as a therapeutic target, while PMID:32641861 discusses CRISPR applications in neurological disease.\n\n**Confidence:** 0.6\n\n## 3. Context-Dependent CRISPR Activation in Specific Neuronal Subtypes\n**Description:** Develop AAV-delivered CRISPR activation systems that selectively target disease-relevant neuronal populations identified through large-scale screening approaches. This precision medicine approach would minimize off-target effects while maximizing therapeutic efficacy in the most vulnerable cell types.\n\n**Target gene/protein:** Cell-type-specific essential genes identified through screening\n\n**Supporting evidence:** PMID:40847019 demonstrates CrAAVe-seq as a scalable platform for identifying neuronal essential genes in specific cell types, providing targets for selective intervention.\n\n**Confidence:** 0.8\n\n## 4. Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting\n**Description:** Engineer CRISPR systems to target and sequester toxic RNA species containing expanded trinucleotide repeats, preventing their translation into harmful proteins or their interference with cellular machinery. This approach could work across multiple repeat expansion diseases.\n\n**Target gene/protein:** HTT, DMPK, and other repeat-containing transcripts\n\n**Supporting evidence:** PMID:36634841 discusses drug development for myotonic dystrophy, indicating the therapeutic potential of targeting repeat-containing RNAs. PMID:32641861 supports CRISPR applications in neurological diseases.\n\n**Confidence:** 0.7\n\n## 5. Programmable Neuronal Circuit Repair via Epigenetic CRISPR\n**Description:** Use CRISPRa/CRISPRi systems to reprogram surviving neurons to adopt molecular signatures of lost neuronal populations, effectively rewiring damaged circuits. This approach could restore functional connectivity without requiring cell replacement.\n\n**Target gene/protein:** Transcription factors defining neuronal identity (e.g., NURR1, PITX3 for dopaminergic neurons)\n\n**Supporting evidence:** PMID:33838111 shows programmable transcriptional memory is achievable, while PMID:32641861 supports CRISPR functional genomics in neurological disease.\n\n**Confidence:** 0.6\n\n## 6. Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring\n**Description:** Develop integrated CRISPR systems that simultaneously perform therapeutic editing and real-time monitoring of treatment efficacy through reporter systems. This theranostic approach would enable personalized dose optimization and early detection of therapeutic resistance.\n\n**Target gene/protein:** Disease-causing mutations with integrated fluorescent reporters\n\n**Supporting evidence:** PMID:40847019 demonstrates sophisticated AAV-based screening platforms, while PMID:32641861 discusses functional genomics applications.\n\n**Confidence:** 0.5\n\n## 7. Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits\n**Description:** Engineer complex CRISPR circuits that coordinately regulate multiple metabolic pathways to shift neurons from vulnerable to resilient metabolic states. This systems-level approach could address the multi-factorial nature of neurodegeneration by simultaneously targeting energy metabolism, protein homeostasis, and stress response pathways.\n\n**Target gene/protein:** PGC1A, SIRT1, FOXO3, and mitochondrial biogenesis genes\n\n**Supporting evidence:** PMID:41062796 emphasizes the importance of metabolic dysfunction in disease, while PMID:33838111 demonstrates the feasibility of coordinated multi-gene regulation.\n\n**Confidence:** 0.6",
  "tokens_used": "1225"
}